Screener Summaries Updates Institutions Sign In More Updates › Other Events › OTLK Other Events · Jun 16, 2026
On June 16, 2026, the FDA acknowledged receipt of the resubmitted Biologics License Application (BLA) for ONS-5010… OTLK Outlook Therapeutics, Inc.
On June 16, 2026, the FDA acknowledged receipt of the resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg). The FDA designated the BLA as a Class 1 review, establishing a 60-day review period and setting a PDUFA goal date of July 29, 2026. Outlook Therapeutics is a biopharmaceutical company developing therapies for ocular diseases.
More from Outlook Therapeutics, Inc. Nasdaq notifies Outlook Therapeutics of non-compliance with $1.00 minimum bid price requirement Sep 30, 2026 Outlook Therapeutics announced that CFO Lawrence A. Kenyon mutually agreed to cease serving as Chief Financial… Aug 27, 2026 On August 12, 2026, Outlook Therapeutics entered into an underwriting agreement for a public offering of 55,555,556… Aug 14, 2026 Outlook Therapeutics reported preliminary cash and cash equivalents of approximately $11.2 million as of June 30, 2026 Aug 12, 2026 On July 21, 2026, Outlook Therapeutics, Inc. announced stock option grants to CEO Robert C. Jahr (100,000 options) and… Jul 23, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
